TY - JOUR
T1 - Advances in the treatment of tuberculosis
AU - Zhang, Y.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2007/11
Y1 - 2007/11
N2 - The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
AB - The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
UR - http://www.scopus.com/inward/record.url?scp=35448999349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35448999349&partnerID=8YFLogxK
U2 - 10.1038/sj.clpt.6100362
DO - 10.1038/sj.clpt.6100362
M3 - Review article
C2 - 17898708
AN - SCOPUS:35448999349
SN - 0009-9236
VL - 82
SP - 595
EP - 600
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 5
ER -